Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chemodex
TIC10
Out of stock
Only %1 left
NEW
| Product Details | |
|---|---|
| Synonyms | ONC201; Dordaviprone; 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one |
| Product Type | Chemical |
| Properties | |
| Formula | C24H26N4O |
| MW | 386.5 |
| CAS | 1616632-77-9 |
| Source/Host Chemicals | Synthetic |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | Yellow solid. |
| Solubility | Soluble in DMF (20mg/ml), ethanol (10mg/ml) or DMSO (10mg/ml). |
| Identity | Determined by 1H-NMR. |
| Declaration | Manufactured by Chemodex. |
| Other Product Data |
Click here for Original Manufacturer Product Datasheet |
| InChi Key | VLULRUCCHYVXOH-UHFFFAOYSA-N |
| Smiles | CC1=CC=CC=C1CN(C2=O)C3=NCCN3C4=C2CN(CC5=CC=CC=C5)CC4 |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Protect from light and moisture. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| Product Specification Sheet | |
| Datasheet |
 Download PDF |
Description
TIC10 (ONC201; Dordaviprone), is a first-in-class imipridone anticancer compound widely used in oncology and cancer biology research. It is orally active, stable, and crosses the blood-brain barrier. TIC10 induces tumor cell apoptosis. As a selective antagonist of the dopamine receptor D2 (DRD2) and an agonist of the mitochondrial protease ClpP, leading to disruption of pro-survival signaling and induction of tumor-selective apoptosis. TIC10 is recognized for its ability to activate the TRAIL (TNF-related apoptosis-inducing ligand) pathway while concurrently inhibiting Akt signaling, a central regulator of cancer cell survival and resistance.
Product References
[1] J.E. Allen, et al.; Sci. Transl. Med. 5, 171ra117 (2013) | [2] J.E. Allen, et al.; Cancer Res. 75, 1668 (2015) | [3] J. Ishizawa, et al.; Sci. Signal. 9, ra17 (2016) | [4] J.E. Allen, et al.; Oncotarget 7, 74380 (2016) (Review) | [5] V.V. Prabhu, et al.; Neoplasia 22, 725 (2020) (Review) | [6] E.R. Bonner, et al.; Neuro-oncology 23, 542 (2021) | [7] B. Shenoy, et al.; Curr